MF1

MF1 is a small molecule inhibitor of fatty acid-binding protein 3 (FABP3), developed by Tohoku University. The compound targets FABP3 and acts by inhibiting its function, with the therapeutic rationale that FABP3 mediates processes relevant to substance dependence and possibly neurodegeneration. Preclinical studies have primarily explored MF1’s potential in nicotine dependence and other drug dependence models, as well as neuroprotection in Parkinson’s disease, though newer, more potent FABP3 inhibitors have supplanted it in recent research. The molecule’s IUPAC name is 4-[2-[5-(2-chlorophenyl)-1-phenylpyrazol-3-yl]phenoxy]butanoic acid, chemical formula C25H21ClN2O3[1][2].

Other names

4-[2-[5-(2-chlorophenyl)-1-phenylpyrazol-3-yl]phenoxy]butanoic acid